10 June 2008
Curidium Medica plc, a leading developer of personalised medicines for Central Nervous System Disorders, has appointed Abchurch Communications to provide ongoing financial communications advice.
Personalised medicines allow for more effective treatments, help minimise the time wasted on less effective medication and reduce drug development costs. Curidium’s proprietary data analysis technology examines large amounts of biological information from patients, including gene expression and protein data. This platform allows patients to be categorised into subgroups, which may have different underlying mechanisms of disease, and are therefore likely to respond differently to treatments. Grouping together patients with a similar ‘molecular signature’, allows the identification of targeted, more effective drug therapies for these individuals.
FinnCap is Nominated Adviser and broker to the Company.
Tel: +44 (0)20 7398 7700